» Articles » PMID: 20025454

Improved Quality of Life, Clinical, and Psychosocial Outcomes Among Heroin-dependent Patients on Ambulatory Buprenorphine Maintenance

Overview
Publisher Informa Healthcare
Date 2009 Dec 23
PMID 20025454
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: A prospective longitudinal design was employed to examine the effects of buprenorphine maintenance on quality of life (QOL), clinical, and psychosocial characteristics of heroin-dependent patients.

Method: Between 2003 and 2005 data were collected on 259 patients attending the outpatient centers for treatment of drug addictions across Israel, of which 157 were reevaluated 16 weeks later and 105 reevaluated 32 weeks later using the Clinical Global Impression, Distress Scale for Adverse Symptoms, Quality of Life Enjoyment and Satisfaction Questionnaire, General Health Questionnaire, General Self-Efficacy Scale, and the Multidimensional Scale of Perceived Social Support. Univariate and multivariate analyses were conducted to examine the association between the parameters and the cross-sectional and longitudinal predictions of the QOL outcomes.

Results: The groups did not differ in baseline values and their post-treatment ratings revealed significant improvement on virtually all the scales. Perceived self-efficacy and social support from friends and significant others at baseline as well as their changes over time were the best predictors of the QOL in the short and long terms. The study's limitations are noted.

Conclusions: The beneficial effects on the QOL were associated with improvement in the psychosocial parameters and a reduction in buprenorphine-related side effects and psychological distress. This study could stimulate research to compare the QOL related to buprenorphine and methadone treatment and serve as a basis on which a controlled study should be performed.

Citing Articles

Growing importance of high-volume buprenorphine prescribers in OUD treatment: 2009-2018.

Schuler M, Dick A, Gordon A, Saloner B, Kerber R, Stein B Drug Alcohol Depend. 2024; 259:111290.

PMID: 38678682 PMC: 11318254. DOI: 10.1016/j.drugalcdep.2024.111290.


Costs of implementing a multi-site facilitation intervention to increase access to medication treatment for opioid use disorder.

Garcia C, Bounthavong M, Gordon A, Gustavson A, Kenny M, Miller W Implement Sci Commun. 2023; 4(1):91.

PMID: 37563672 PMC: 10413546. DOI: 10.1186/s43058-023-00482-8.


Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment.

Stein B, Saloner B, Golan O, Andraka-Christou B, Andrews C, Dick A JAMA Health Forum. 2023; 4(5):e231102.

PMID: 37234015 PMC: 10220518. DOI: 10.1001/jamahealthforum.2023.1102.


Buprenorphine use and courses of care for opioid use disorder treatment within the Veterans Health Administration.

Gordon A, Saxon A, Kertesz S, Wyse J, Manhapra A, Lin L Drug Alcohol Depend. 2023; 248:109902.

PMID: 37196572 PMC: 10875624. DOI: 10.1016/j.drugalcdep.2023.109902.


Subsequent Buprenorphine Treatment Following Emergency Physician Buprenorphine Prescription Fills: A National Assessment 2019 to 2020.

Stein B, Saloner B, Kerber R, Sorbero M, Gordon A Ann Emerg Med. 2022; 79(5):441-450.

PMID: 35305851 PMC: 9038689. DOI: 10.1016/j.annemergmed.2022.01.042.